WaveData

Track

Track 2 beckons innovators to find ways to expedite every stage of clinical trials, from design to data analysis, focusing on enhancing speed, quality, cost-effectiveness, and overall participant experience.

Inspiration

Orphan drugs offer important health benefits to patients, but they challenge traditional health technology assessment, reimbursement, and pricing processes due to limited evidence on their effectiveness. The result is that uncertainty about the benefits in real life practice cause a delay in pricing & reimbursement decisions by payers.

Also we see in our society that artificial intelligence (AI) is everywhere and is already making important decisions in our daily life. AI can create many positive impacts, but we also have big challenges like racist decisions. Most things in our society are built for, and designed around, a specific “reference man." This “standard human” is usually a white male in his 30s who weighs around 155 pounds. The reference man is the default user in many parts, like cars, air-conditioned offices, city streets and especially healthcare. When it comes to healthcare, we see that it has deadly effects for women and BAME.

A big problem is that we need inclusive data to create inclusive AI modules, however medical researchers have a hard time finding people and convincing them to share their health data. People are however very eager to help when they realize their data can make a difference. This works even better with diseases they have a connection to through a family member or a friend. The global clinical trials market size was estimated at USD 44.3 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 5.7% from 2021 to 2028.

What it does

Github: https://github.com/wavedata/wavedata.trial Website: https://wavedata-trial.vercel.app/ App: https://wavedata-trial-app.vercel.app/

Personalized trial experience for better clinical trial outcomes. WaveData make clinical trials more transparent, fund and easy. WaveData is based on two things: (1) Decentralized marketplace where organizations (universities/hospitals/pharma) can create a clinical trial and also get data from the people that join the clinical trial. (2) App that people will use during the clinical trial, get recommendations in which trials they can participate and get points.

WaveData connects people who want to help with medical researchers who need data. The biggest difference with existing platforms is that we approach the problem from the side of the people who want to help cure a disease. When someone you love has cancer or Alzheimers you feel helpless, and you want to do something about it. WaveData is built on the TRON wallet to provide a safe and secure way to share your data. We can see that pharmaceutical companies would be interested in the same data. It's up to you if you give them permission to look at your data. Also, users can earn points to stay motivated during the clinical trial. With the WaveData marketplace the organizer can create their trials and surveys and set the questions, rewards etc. With the WaveData app, people can download a user-friendly app to survey and join trials. WaveData helps each user and organizer to keep touch every day. On WaveData the organizer can check how many people have contributed and what their answers are. WaveData provides chart analysis options for the organizer to keep updated with better understanding.

Crucial stakeholder motivation

(1) Medical research facilities - we help them connecting to people who are willing to share their data (2) Patients' interests’ associations - give them an opportunity to combat the disease through the sharing of data. (3) Pharmaceutical Companies - an opportunity to have access to data if allowed by the people (4) Everybody - a way to help combat diseases that can be trusted because your personal data are secure (5) Government - Aiding healthcare research through robust security for personal data

How we built it

React js, Nodejs, Next js, Flutter, web3, css, solidity, json, javascript, typescript, html, js, jsx, ts, tsx, FHIR (HL7)

Accomplishments that we're proud of

We are very proud that we build a product that will create value for clinical trials, better RWE and one of the biggest challenges at this moment, no racism in healthcare outcomes. The project is pretty big, and we are beginning programmers, which was sometimes a challenge. With our positive behavior we worked together and made not one, but two working applications. What's next for WaveData: Your data is the cure! WaveData will create new value for clinical trials by making clinical trials more transparent, fun and easy, so everybody can join with the goal to create inclusive AI! We have spoken with many medical researchers and they all mentioned the huge problem of creating good clinical trials, because it takes months and sometimes even years to include people and there's also a huge chance that people will drop out. The process is too difficult, takes time and people don’t know where to find clinical trials. To understand the reason why people are not joining clinical trials we did some focus groups and talked with random people on the street. Conclusion is that people really want to help, because almost everyone knows someone with a disease. The problem is the transparency of the processes, the value by joining a clinical trial and besides that, they often get nothing for it directly. In 2022 there were more than 400.000 clinical trials and with a market size of 44.3 billion USD in 2020 it’s one of the biggest markets. Besides that, we have a big network in the healthcare field, which means that we can start a pilot with WaveData in the coming months. Also, the gamification part in combination with getting points will motivate participants and join other clinical trials. The power is to do it together and that will be the USP from WaveDate, because we want to make clinical trials accessible for everyone and make it fun! For investment strategy we see that FemTech will grow extremely fast in the coming years, with a value of over 60 billion dollars by 2027.